94 related articles for article (PubMed ID: 23319808)
21. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
22. p53 mutation is common in microsatellite stable, BRAF mutant colorectal cancers.
Bond CE; Umapathy A; Ramsnes I; Greco SA; Zhen Zhao Z; Mallitt KA; Buttenshaw RL; Montgomery GW; Leggett BA; Whitehall VL
Int J Cancer; 2012 Apr; 130(7):1567-76. PubMed ID: 21557216
[TBL] [Abstract][Full Text] [Related]
23. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy.
Yoon J; Koo KH; Choi KY
Cancer Res; 2011 Jan; 71(2):445-53. PubMed ID: 21118963
[TBL] [Abstract][Full Text] [Related]
24. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.
Ikenoue T; Hikiba Y; Kanai F; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Aragaki J; Matsumura M; Kawabe T; Omata M
Cancer Res; 2003 Dec; 63(23):8132-7. PubMed ID: 14678966
[TBL] [Abstract][Full Text] [Related]
25. Transfection of constitutively active mitogen-activated protein/extracellular signal-regulated kinase kinase confers tumorigenic and metastatic potentials to NIH3T3 cells.
Welch DR; Sakamaki T; Pioquinto R; Leonard TO; Goldberg SF; Hon Q; Erikson RL; Rieber M; Rieber MS; Hicks DJ; Bonventre JV; Alessandrini A
Cancer Res; 2000 Mar; 60(6):1552-6. PubMed ID: 10749122
[TBL] [Abstract][Full Text] [Related]
26. BRAF V600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells.
Sueda T; Sakai D; Kawamoto K; Konno M; Nishida N; Koseki J; Colvin H; Takahashi H; Haraguchi N; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Satoh T; Doki Y; Mori M; Ishii H
Sci Rep; 2016 Jan; 6():18949. PubMed ID: 26750638
[TBL] [Abstract][Full Text] [Related]
27. Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer.
Seiden-Long IM; Brown KR; Shih W; Wigle DA; Radulovich N; Jurisica I; Tsao MS
Oncogene; 2006 Jan; 25(1):91-102. PubMed ID: 16158056
[TBL] [Abstract][Full Text] [Related]
28. Oncogenic KRAS provides a uniquely powerful and variable oncogenic contribution among RAS family members in the colonic epithelium.
Keller JW; Franklin JL; Graves-Deal R; Friedman DB; Whitwell CW; Coffey RJ
J Cell Physiol; 2007 Mar; 210(3):740-9. PubMed ID: 17133351
[TBL] [Abstract][Full Text] [Related]
29. Mutations of the BRAF gene in ulcerative colitis-related colorectal carcinoma.
Aust DE; Haase M; Dobryden L; Markwarth A; Löhrs U; Wittekind C; Baretton GB; Tannapfel A
Int J Cancer; 2005 Jul; 115(5):673-7. PubMed ID: 15704157
[TBL] [Abstract][Full Text] [Related]
30. Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies.
Kuracha MR; Thomas P; Loggie BW; Govindarajan V
PLoS One; 2017; 12(6):e0179510. PubMed ID: 28640835
[TBL] [Abstract][Full Text] [Related]
31. Radicicol suppresses transformation and restores tropomyosin-2 expression in both ras- and MEK-transformed cells without inhibiting the Raf/MEK/ERK signaling cascade.
Kim PN; Jonasch E; Mosterman BC; Mier JW; Janssen RA
Cell Growth Differ; 2001 Nov; 12(11):543-50. PubMed ID: 11714635
[TBL] [Abstract][Full Text] [Related]
32. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression.
Oliveira C; Velho S; Moutinho C; Ferreira A; Preto A; Domingo E; Capelinha AF; Duval A; Hamelin R; Machado JC; Schwartz S; Carneiro F; Seruca R
Oncogene; 2007 Jan; 26(1):158-63. PubMed ID: 16953233
[TBL] [Abstract][Full Text] [Related]
33. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
Migliardi G; Sassi F; Torti D; Galimi F; Zanella ER; Buscarino M; Ribero D; Muratore A; Massucco P; Pisacane A; Risio M; Capussotti L; Marsoni S; Di Nicolantonio F; Bardelli A; Comoglio PM; Trusolino L; Bertotti A
Clin Cancer Res; 2012 May; 18(9):2515-25. PubMed ID: 22392911
[TBL] [Abstract][Full Text] [Related]
35. MLK4 regulates DNA damage response and promotes triple-negative breast cancer chemoresistance.
Mehlich D; Łomiak M; Sobiborowicz A; Mazan A; Dymerska D; Szewczyk ŁM; Mehlich A; Borowiec A; Prełowska MK; Gorczyński A; Jabłoński P; Iżycka-Świeszewska E; Nowis D; Marusiak AA
Cell Death Dis; 2021 Nov; 12(12):1111. PubMed ID: 34839359
[TBL] [Abstract][Full Text] [Related]
36. Cancer signaling: when phosphorylation meets methylation.
Ying H; DePinho RA
Cell Res; 2014 Nov; 24(11):1282-3. PubMed ID: 25104733
[TBL] [Abstract][Full Text] [Related]
37. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.
Misale S; Arena S; Lamba S; Siravegna G; Lallo A; Hobor S; Russo M; Buscarino M; Lazzari L; Sartore-Bianchi A; Bencardino K; Amatu A; Lauricella C; Valtorta E; Siena S; Di Nicolantonio F; Bardelli A
Sci Transl Med; 2014 Feb; 6(224):224ra26. PubMed ID: 24553387
[TBL] [Abstract][Full Text] [Related]
38. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression.
Janssen KP; Alberici P; Fsihi H; Gaspar C; Breukel C; Franken P; Rosty C; Abal M; El Marjou F; Smits R; Louvard D; Fodde R; Robine S
Gastroenterology; 2006 Oct; 131(4):1096-109. PubMed ID: 17030180
[TBL] [Abstract][Full Text] [Related]
39. Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy.
Alves S; Castro L; Fernandes MS; Francisco R; Castro P; Priault M; Chaves SR; Moyer MP; Oliveira C; Seruca R; Côrte-Real M; Sousa MJ; Preto A
Oncotarget; 2015 Oct; 6(31):30787-802. PubMed ID: 26418750
[TBL] [Abstract][Full Text] [Related]
40. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
